Aims: To describe the characteristics and treatment of patients with type 2 diabetes mellitus initiating a second-line glucose-lowering therapy in the global DISCOVER study programme.
Introduction
An estimated 425 million adults had diabetes worldwide in 2017, and this number is predicted to rise to 629 million by 2045 [1] . Type 2 diabetes mellitus accounts for approximately 90% of cases. This increase in the prevalence of type 2 diabetes mellitus will result in a large economic and social burden, and is likely to occur predominantly in low-to middle-income countries, where approximately threequarters of people with type 2 diabetes mellitus live [1] .
Cross-sectional studies have clearly demonstrated that glycaemic control and management of comorbidities are suboptimal in both high-income [2, 3] and low-to medium-income countries [4, 5] . In many regions, however, longitudinal data on glucose-lowering treatment patterns and associated outcomes are scarce or non-existent. Sustained glycaemic control, along with the management of comorbidities such as hypertension and hyperlipidaemia, remains a key component of the effective treatment of patients with type 2 diabetes mellitus. Clinical guidelines recommend the use of metformin, in conjunction with lifestyle changes, as the first-line glucose-lowering therapy [6] [7] [8] [9] [10] [11] . However, when metformin monotherapy fails to control glycated haemoglobin (HbA 1c ) levels, there is no consensus on optimal subsequent treatments, and guidelines recommend an individualized and patient-centred approach to drug selection based on patient characteristics including age, duration of diabetes, presence of comorbidities and risk of adverse events including hypoglycaemia and weight gain [8] . Beyond glycaemic control, recent large cardiovascular outcome trials [12] [13] [14] [15] and a large multinational observational study [16] have shown that some glucose-lowering therapies significantly reduce the risk of cardiovascular complications in patients with high cardiovascular risk, suggesting that treatment patterns may have a significant effect on the development of diabetes-related complications.
DISCOVER is a programme of observational research involving 15,992 patients with type 2 diabetes mellitus moving from a first-line to a second-line glucose-lowering therapy in 38 countries across six continents. First-and second-line treatments could be mono or combination therapies, and patients who were prescribed an injectable agent as firstline therapy were excluded. The aim of the study is to provide a global picture of type 2 diabetes mellitus treatment and clinical outcomes, including in many rarely studied low-and middle-income countries. The use of standardized data collection methodology allows comparison between regions and countries. Patients initiating second-line therapy were chosen as the focus of the study because of the diversity of treatment options recommended at this stage of disease progression. The aim of the present analysis was to describe the baseline characteristics and treatment of patients enrolled in the study, and to compare these characteristics between regions. The sampling methodology and diversity of clinical sites from which patients have been recruited is also described.
Subjects, materials and methods
The design and methodology of the DISCOVER study programme have been reported in detail elsewhere [17, 18] and are briefly summarized below.
Study design
The DISCOVER study programme comprises two similar, 3-year, prospective, observational (non-interventional) studies conducted simultaneously in 38 countries: DISCOVER (NCT02322762) in 37 countries (Algeria, Argentina, Australia, Austria, Bahrain, Brazil, Canada, China, Colombia, Costa Rica, Czech Republic, Denmark, Egypt, France, India, Indonesia, Italy, Jordan, Kuwait, Lebanon, Malaysia, Mexico, the Netherlands, Norway, Oman, Panama, Poland, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Taiwan, Tunisia, Turkey and the United Arab Emirates), and J-DISCOVER (NCT02226822) in Japan. The study protocol was approved by the appropriate clinical research ethics committees in each country, and the relevant institutional review boards at each site. The protocol complies with the Declaration of Helsinki, the International Conference on Harmonisation of Good Clinical Practice and the local regulations for clinical research.
Site and investigator selection
The characteristics of physicians and practices involved in the management of patients with type 2 diabetes mellitus in each country were explored before starting the study, in order to recruit as representative as possible a selection of physicians and patients. Information was collated from peer-reviewed articles, reports published by international organizations such as the World Health Organization, and from local diabetes experts who acted as coordinating investigators in each country. Healthcare system characteristics considered included the proportions of different types of health care provider (primary care physicians, diabetologists, endocrinologists, cardiologists and other specialists) and practices (primary care centres, specialized diabetes centres and different types of hospitals) treating patients with type 2 diabetes mellitus in each country, as well as location (urban vs. rural and geographical distribution within a country) and funding source (public, private and mixed). A list of candidate sites that would match these characteristics as closely as possible was then established for each country, and all of these sites were invited to participate in the study. Among the invited sites, approximately one-third were subsequently able to take part and recruited patients into the study.
Patient recruitment
Inclusion and exclusion criteria were kept to a minimum to reflect routine clinical practice (Supplementary Table 1) . Patients with type 2 diabetes mellitus initiating a secondline glucose-lowering treatment (add-on or switching) after first-line oral treatment with a monotherapy, dual therapy or triple therapy were invited by their physician to participate in the study. Patients using an injectable agent (ie, insulin or a glucagon-like peptide-1 [GLP-1] receptor agonist) as first-line therapy were excluded from the study, as they are likely to represent a group of patients with a more severe disease profile who should be studied separately. The study protocol stated that investigating physicians should invite consecutive eligible patients to take part in the study. All participating patients provided signed informed consent.
Data collection
Data at baseline (initiation of second-line therapy) were collected using a standardized electronic case report form, and were transferred to a central database via a web-based data capture system. Some data were extracted from existing electronic medical records and health registries in Canada, Denmark, France, Norway and Sweden; an abbreviated electronic case report form was used in these countries. 
Results

Site characteristics
A total of 778 sites in 38 countries are participating in the study programme ( Where possible, we compared the characteristics of included sites and investigators to the information collated before the start of the study for each country. The results of this comparison are shown in Supplementary Fig. 2 . Overall, some over-representation of sites from urban locations and specialist care centres was identified. 
Patient socio-demographics
A total of 15,992 patients were enrolled in the study programme (Supplementary Fig. 1 ; Table 2 ). Participants were mostly Asian (49.7%) or Caucasian (25.6%), and 54.2% (ARR: 37.7-58.6%) were male. At the time of initiation of secondline therapy, patients' mean age was 57.2 years (SD: 12.0 years) with the highest mean age in Europe (61.9 years) and the lowest in South-East Asia (53.1 years). A total of 52.3% (ARR: 42.4-63.1%) of patients were aged 41-60 years. Overall, 48.9% of patients were employed or self-employed (ARR: 39.4-55.5%), 28.0% were unemployed (ARR: 15.8-41.8%), and 22.2% were retired (ARR: 9.9-43.0%). The highest rates of unemployment were recorded in Africa (41.8%) and South-East Asia (41.4%), and the lowest in Europe (15.8%). Overall, 21.3% of patients did not have health insurance; this proportion varied greatly across regions from 4.0% in Europe to 67.8% in South-East Asia; overall, 62.5% of patients were covered by public health insurance (ARR: 11.7-91.3%). >80% of patients had received secondary or higher education (ARR: 68.1-88.9%). Most participants stated that they were lifetime non-smokers (69.4%; ARR: 56.1-91.7%) and lifetime alcohol abstainers (65.8%; ARR: 44.9-92.6%).
Patient baseline clinical variables
Clinical variables at baseline are reported in ). Hypertension and hyperlipidaemia were recorded as comorbid conditions by the investigators for 51.5% and 45.6% of patients, respectively. Systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) levels were reported for 95.4% and 54.8% of patients, respectively. Among these patients, 67.7% had an SBP lower than 140 mmHg, and 43.4% had an LDL-C level lower than 100 mg/dl. Microvascular complications (history of chronic kidney disease, retinopathy, retinal laser photocoagulation, autonomic neuropathy, peripheral neuropathy and erectile dysfunction), and macrovascular complications (history of coronary artery disease, heart failure, angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, stroke, transient ischaemic attack, carotid artery stent, carotid endarterectomy, peripheral artery disease, diabetic foot, amputation and defibrillator use) were present in 18.9% (ARR: 14.5-23.5%) and 12.7% (ARR: 4.0-26.6%) of patients, respectively.
3.4.
First-and second-line therapies
First-and second-line therapies are described in Table 4 . The most prescribed first-line therapies were metformin monotherapy (55.6%; ARR: 42.5-83.6%) and combinations of metformin and a sulfonylurea (14.4%; ARR: 5.8-31.1%). The proportion of patients who received combinations of metformin and a sulfonylurea as first-line therapies was particularly high in South-East Asia and the Eastern Mediterranean region (31.1% and 23.9%, respectively). Overall, the most prescribed second-line therapies were combinations of metformin and a dipeptidyl peptidase-4 (DPP-4) inhibitor (23.5%) and combinations of metformin and a sulfonylurea (20.9%). Combinations of metformin and a sulfonylurea were the most commonly prescribed secondline therapies in Africa (57.1%) and South-East Asia (24.8%), and combinations of metformin and a DPP-4 inhibitor were the most commonly prescribed second-line therapies in the Eastern Mediterranean region (29.6%), the Americas (29.2%), Europe (27.5%) and the Western Pacific region (24.8%). Monotherapies accounted for 12.8% of second-line treatments, but this proportion varied across regions (ARR: 4.9-15.8%). The overall prescription rate of insulin (on its own or as part of a combination) was 7.8% (ARR: 4.7-10.7%). Of the 1237 patients who received insulin, 957 (77.4%) had an HbA 1c measurement; mean HbA 1c was 9.9% (SD: 2.1%) (data not shown).
The main reason for initiating a second-line therapy reported by investigators was lack of efficacy of first-line therapy (88.9%) (Fig. 1a) , and the main reasons for choosing second-line treatments were efficacy (61.4%), tolerability (22.3%), low risk of weight gain (17.8%) and low risk of hypoglycaemic events (17.0%) (Fig. 1b) . Lack of efficacy was also the main reason reported for switching between monotherapies (data not shown).
Discussion
DISCOVER is a unique, global research programme that assesses the characteristics, treatment and outcomes of patients with type 2 diabetes mellitus after initiating second-line glucose-lowering therapy. DISCOVER includes 778 clinical sites representing primary and secondary care, rural and urban locations, and different funding sources. [19] . Our results suggest that, in such situations, other measures of glycaemia such as PPG, FPG and selfmonitoring of blood glucose may have been used by some physicians as alternatives to monitor glucose levels and to support treatment decisions in routine clinical practice. However, 7.1% of patients had no recorded measure of blood glucose levels, a higher proportion than would be expected since all patients were changing treatment at the time of their inclusion in the study.
As expected in a population of patients who were escalating from first-to second-line therapy, mean HbA 1c levels were above the target of 7.0% recommended by guidelines [8, 10] . Mean HbA 1c levels were largely similar across all regions and were consistently high. Overall, >50% of patients for whom HbA 1c levels were reported had a measurement higher than 8.0%, and approximately 30% had a measurement higher than 9.0%. This suggests suboptimal glycaemic control and delayed treatment intensification in a large proportion of patients, increasing their risk of microvascular and macrovascular complications [20, 21] . The prevalence of vascular complications and associated risk factors (hypertension and hyperlipidaemia) also highlighted an opportunity to improve the early management of patients with type 2 diabetes mellitus.
The most common first-line therapy was metformin monotherapy in all regions. However, overall only 55.6% of all patients received metformin monotherapy at first-line, a lower proportion than has been reported in some recent retrospective observational studies conducted in Western countries [22] [23] [24] [25] . In these studies, 65-91% of patients newly diagnosed with type 2 diabetes mellitus received metformin monotherapy as first-line treatment. This difference may be explained, at least in part, by lower metformin monotherapy usage in South-East Asia, the Eastern Mediterranean and the Western Pacific, where less than 50% of patients were prescribed metformin monotherapy at first line. The proportions of patients receiving metformin monotherapy as first-line treatment in Africa, the Americas and Europe were 83.6%, 77.1% and 67.1%, respectively; similar to the previous reports [22] [23] [24] [25] .
Overall and in Africa, South-East Asia, Europe and the Eastern Mediterranean region, the second most commonly prescribed first-line treatment consisted of a combination of Health insurance coverage Private metformin and a sulfonylurea. Prescription of combination therapies as first-line treatment may reflect initiation of pharmacological therapy in patients with high HbA 1c levels; physicians may have adopted a similar approach to the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) treatment algorithm, which recommends the use of metformin with a second agent for newly diagnosed patients with an HbA 1c level of 7.5% or more [8] . It should be noted, however, that combinations of metformin and sulfonylureas come last in the hierarchy of first-line therapies suggested by the AACE/ACE for patients with an HbA 1c level of 7.5% or more. Alternatively, physicians may prescribe lower doses of more than one medication in order to address more than one physio-pathologic aspect of the disease, and reduce the risk of adverse events.
The high prevalence of the use of combinations of metformin and sulfonylureas is likely to be driven by the low cost of these drugs rather than clinical evidence, particularly in low-to middle-income countries. In addition, many countries participating in DISCOVER have limited formularies, with sodium-glucose-linked transporter type 2 inhibitors and DPP-4 inhibitors being rarely available [26, 27] . Slightly more than 20% of patients received a first-line therapy that did not include metformin. Second-line therapies varied greatly across regions. The most prescribed second-line therapies were combinations of metformin and a sulfonylurea (Africa, South-East Asia and the Western Pacific region), and combinations of metformin and a DPP-4 inhibitor (Americas, Europe and the Eastern Mediterranean region). Of note, approximately 13% of patients received a single glucose-lowering agent as secondline therapy, suggesting that many patients switched between monotherapies. Although switching between monotherapies may be appropriate for patients who did not tolerate their first-line treatment, such switches are not in line with guideline recommendations for the majority of patients for whom lack of efficacy was reported as a reason for treatment change [6] [7] [8] [9] [10] [11] . Insulin (on its own or as part of a combination) was prescribed in 7.8% of patients, for whom the mean HbA 1c level was 9.9%. This high mean HbA 1c level was similar to levels reported in other observational studies of patients initiating insulin [28, 29] and is consistent with the recommendations of clinical guidelines [6, 8, 10] .
Strengths and limitations
The DISCOVER study programme includes nearly 16,000 patients, with global coverage including many countries that have rarely or never been studied before regarding the management and outcomes of patients with type 2 diabetes mellitus. Previous international studies have usually focussed on patients with more advanced disease; for example, A 1 chieve and IMPROVE both studied patients receiving insulin therapy, and the International Diabetes Management Practice Study included patients with a mean diabetes duration of 8.4 years [5] . DISCOVER therefore provides unique insights into treatment practices at an earlier point in disease progression, at a stage where guideline recommendations diversify. Longterm follow-up will provide an opportunity to assess the associations between treatment choices and clinical outcomes. Data are reported as n (%), unless otherwise stated. Percentages calculated for all patients with data available; missing data are excluded.
a Microvascular complications included a history of chronic kidney disease, retinopathy, retinal laser photocoagulation, autonomic neuropathy, peripheral neuropathy and erectile dysfunction.
b Macrovascular complications included a history of coronary artery disease, heart failure, angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, stroke, transient ischaemic attack, carotid artery stent, carotid endarterectomy, peripheral artery disease, diabetic foot, amputation and implantable cardioverter defibrillator use. The large population size of DISCOVER will provide the opportunity to analyse events with low incidences, and the use of a standardized electronic case report form for data collection allows the comparison of results within and across countries and regions. Although sites were carefully selected to be as representative as possible of the management of type 2 diabetes mellitus in each participating country, as in any observational study of this nature it was not possible to obtain a fully representative sample ( Supplementary Fig. 1 ). There are several reasons for this including low numbers of sites in some countries, infrastructure challenges that prevented the inclusion of some sites in rural locations, and the fact that some centres, often those involved in primary care, did not have the capability of running observational research or failed to meet other quality requirements. In some countries, little information was available to be collated before the start of the study.
Patient selection bias should also be considered; for example, more than three-quarters of participants were reported to have secondary or higher education, a greater proportion than would be anticipated and potentially reflecting an increased willingness among educated patients to take part in the study. In addition, less than a third of patients reported alcohol or tobacco use, which may indicate selective disclosure or suppression of information. Together, these observations may also reflect a selection bias for patients of higher socio-economic status, which should be considered when interpreting the results from the DISCOVER study. Indeed, these patients are likely to receive better care and therefore to have better outcomes than the general population of patients initiating a second-line glucose-lowering therapy.
Nevertheless, the patient population included in DIS-COVER is large and heterogeneous, resulting in a unique opportunity to assess associations between clinical outcomes, treatment options and other factors in a global context. Over-representation of urban locations, secondary care and highly educated patients is likely to lead to an over-estimate, rather than an underestimate, of the quality of care in at least some countries. Another possibility is that over-representation of secondary care may result in the inclusion of patients with more severe disease, who are more likely to be referred to hospitals and for specialist management. The observational design of DISCOVER also means that data are collected in accordance with routine clinical practice at each participating site. Data collection was not mandatory for any variable, and the study protocol did not specify standardized methods to measure clinical variables such as HbA 1c . Methodology may therefore vary across sites and countries. The results, however, are reflective of clinical practice. Finally, events such as occurrence of complications were not adjudicated, and diagnosis relied on the judgement of treating physicians.
Conclusions
Baseline data from the DISCOVER study highlight substantial variations in healthcare systems, characteristics and treatment of patients with type 2 diabetes mellitus between geographic regions. The great diversity of prescribed treatments confirms that uncertainty remains regarding the optimal choice of second-line therapy in clinical practice. Among this population of patients initiating second-line therapy, HbA 1c levels and the prevalence of vascular complications and associated risk factors were high, highlighting a global need for more aggressive risk-factor management. The 3-year followup of DISCOVER patients will allow the comparison of outcomes associated with different therapies, thus providing insights on the optimal use of available glucose-lowering drugs.
